Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 12, Issue 9, Pages 1061-1076Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.12.59
Keywords
multiple sclerosis; neurodegeneration; neuronal injury; neuroprotection; treatment
Categories
Funding
- Teva
- Novartis
- Merck Serona
- Bayer
- Johnson Johnson
- Ono
- Octapharma
Ask authors/readers for more resources
In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available